Vertex (VRTX) PT Raised to $161 at Piper Jaffray Following ORKAMBI Approval
Get Alerts VRTX Hot Sheet
Rating Summary:
31 Buy, 10 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Join SI Premium – FREE
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and boosted its price target on Vertex (NASDAQ: VRTX) to $161.00 (from $146.00) following FDA approval of ORKAMBI. The approval will drive top-line results and profits, according to the analyst.
Tenthoff commented, "CONCLUSION Last Thursday, 7/2, the FDA approved ORKAMBI in homozygous F508del cystic fibrosis patients aged 12 and older. Vertex announced annual ORKAMBI pricing of $259,000, which was below our expectation of "in-line with KALYDECO," but still above Street consensus. Applying a gross-to-net discount of 20%, we are lowering our total CF sales forecast to $883 million from $1.0 billion this year, to $2.4 billion from $3.1 billion in 2016 and introducing a 2017 forecast of $3.2 billion. This ramp in sales will result in sustained profitability with non-GAAP EPS now at $3.15 in 2016 and $5.69 in 2017. We reiterate our Overweight rating and are increasing our price target to $161 from $146 by applying the same 35x multiple now to 2017 Non-GAAP EPS discounted back at 15% through mid'16."
The firm trimmed FY 2015 EPS from ($2.20) to ($2.73) and FY 2016 EPS from $3.54 to $1.53.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $131.26 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades STO Express Co Ltd (002468:CH) to Neutral
- Canaccord Genuity Downgrades Antofagasta Plc. (ANTO:LN) (ANFGF) to Hold
- Morgan Stanley Upgrades EPAM Systems (EPAM) to Equalweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Piper Jaffray, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!